Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001939868 | SCV002186744 | uncertain significance | not provided | 2021-09-17 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with tryptophan at codon 702 of the EPS8 protein (p.Arg702Trp). The arginine residue is moderately conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is present in population databases (rs201426875, ExAC 0.1%). This variant has not been reported in the literature in individuals affected with EPS8-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV003146343 | SCV003833549 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 102 | 2019-10-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004975848 | SCV005572805 | uncertain significance | Inborn genetic diseases | 2024-08-27 | criteria provided, single submitter | clinical testing | The c.2104C>T (p.R702W) alteration is located in exon 19 (coding exon 18) of the EPS8 gene. This alteration results from a C to T substitution at nucleotide position 2104, causing the arginine (R) at amino acid position 702 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |